{{Rsnum
|rsid=2257212
|Gene=SLC15A2
|Chromosome=3
|position=121924957
|Orientation=minus
|GMAF=0.4908
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=SLC15A2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 19.5 | 54.0 | 26.5
| HCB | 54.0 | 40.9 | 5.1
| JPT | 59.3 | 36.3 | 4.4
| YRI | 26.5 | 51.7 | 21.8
| ASW | 17.5 | 43.9 | 38.6
| CHB | 54.0 | 40.9 | 5.1
| CHD | 53.2 | 40.4 | 6.4
| GIH | 11.9 | 39.6 | 48.5
| LWK | 20.0 | 47.3 | 32.7
| MEX | 8.6 | 29.3 | 62.1
| MKK | 31.4 | 38.5 | 30.1
| TSI | 8.8 | 49.0 | 42.2
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2257212
|Name_s=SLC15A2: F350L
|Gene_s=SLC15A2
|Feature=Exon/NonSyn
|Evidence=PubMed ID:19940846
|Annotation=PEPT2*1 (350L-409P-509R) showed lower K m for glycyl-sarcosine as compared with PEPT2*2 (350F- 409S-509K) in transfected cells.
|Drugs=glycyl-sarcosine
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA165111598
}}

{{GET Evidence
|gene=SLC15A2
|aa_change=Leu350Phe
|aa_change_short=L350F
|impact=not reviewed
|qualified_impact=Insufficiently evaluated not reviewed
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2257212
|overall_frequency_n=5030
|overall_frequency_d=10754
|overall_frequency=0.467733
|n_genomes=41
|n_genomes_annotated=0
|n_haplomes=51
|n_articles=0
|n_articles_annotated=0
|nblosum100=0
|autoscore=0
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}